V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 240012511 | 240008705 | 1.72 | 95.5 | Curative (C) | 2017-08-13 | 2017-08-16 | Bortezomib + Cyclophos + Dex | null | null | 240011182 | CVD |
| 240012512 | 240008706 | 1.73 | 63 | Palliative (P) | 2015-03-12 | 2015-03-25 | CLOFARABINE | N | N | 240011194 | CARMUSTINE + THIOTEPA |
| 240012513 | 240008707 | 1.54 | 49.5 | Palliative (P) | 2017-04-05 | 2017-04-06 | MABCUTE TRIAL | 01 | null | 240011315 | GALLIUM TRIAL |
| 240012514 | 240008707 | null | 68.2 | Curative (C) | 2017-03-14 | 2017-05-16 | BLEOMYCIN + CHLORAMBUCIL + LOMUSTINE + METHOTREXATE + RITUXIMAB + VINBLASTINE | 02 | N | 240011315 | CYTARABINE + RITUXIMAB |
| 240012515 | 240008709 | 1.62 | 55.2 | Disease modification (D) | 2015-02-27 | 2015-02-27 | ICE-R (Cycle 2 onwards) | N | N | 240011435 | AML17 TRIAL |
| 240012516 | 240014504 | 1.59 | 40 | Neo-adjuvant (N) | 2014-08-14 | 2014-08-27 | RCEOP | N | N | 240011485 | ICE-R |
| 240012517 | 240012650 | 1.61 | 65.4 | Palliative (P) | 2018-11-09 | 2018-11-12 | PEMBROLIZUMAB | 01 | N | 240011523 | CARBOPLATIN + LIPOSOMAL DOX |
| 240012518 | 240008714 | 1.84 | 78.8 | Not known (9) | 2018-06-14 | 2018-06-26 | BLEOMYCIN + CHLORAMBUCIL + LOMUSTINE + METHOTREXATE + RITUXIMAB + VINBLASTINE | 02 | N | 240011523 | ETOPOSIDE + IFOSFAMIDE + RITUXIMAB |
| 240012519 | 240012654 | 1.84 | 93.6 | Palliative (P) | 2016-02-22 | 2016-02-22 | VEDex | 2 | null | 240011596 | ETOPOSIDE |
| 240012520 | 240015435 | null | 70 | Palliative (P) | null | 2016-12-08 | ICE (no GCSF) | 02 | N | 240011596 | PIXANTRONE |
| 240012521 | 240008719 | 1.68 | null | Palliative (P) | 2016-07-19 | 2016-07-21 | CHOEP | N | N | 240011697 | ERLOTINIB |
| 240012522 | 240008720 | 1.72 | 80.4 | Curative (C) | 2016-07-13 | 2016-08-11 | R CODOX M | N | Y | 240011697 | CAPECITABINE |
| 240012523 | 240014508 | null | 62.4 | Palliative (P) | 2018-11-21 | 2018-11-29 | ETOPOSIDE | null | N | 240011790 | CTD |
| 240012524 | 240008722 | 1.66 | null | Disease modification (D) | 2017-12-22 | 2018-02-11 | IVE | N | null | 240011993 | AML16 TRIAL |
| 240012525 | 240008723 | 1.72 | 77 | Palliative (P) | 2017-07-28 | 2017-08-17 | R CODOX M | N | N | 240012046 | RCEOP |
| 240012526 | 240008724 | 1.63 | 61.8 | Palliative (P) | 2014-10-06 | 2014-10-09 | GEMCITABINE + OXALIPLATIN + RITUXIMAB | N | null | 240012059 | IVAC |
| 240012527 | 240008724 | 1.79 | 93.5 | Curative (C) | 2018-05-20 | 2018-05-21 | Cyclophosphamide + Etoposide (PO) | 2 | N | 240012059 | IVE |
| 240012528 | 240008725 | 1.71 | 99.4 | Palliative (P) | 2016-03-31 | 2016-04-04 | AML 19 TRIAL | 2 | N | 240012194 | CYTARABINE + RITUXIMAB |
| 240012529 | 240008726 | 1.71 | 69.4 | Curative (C) | 2017-09-29 | 2017-09-29 | MERCAPTOPURINE + METHOTREXATE + VINCRISTINE | N | null | 240012212 | REMODL TRIAL |
| 240012530 | 240008727 | 1.71 | null | Palliative (P) | 2017-06-13 | 2017-06-13 | VINCRISTINE | 02 | N | 240012243 | CAV |
| 240012531 | 240008727 | 1.74 | 79.5 | Disease modification (D) | 2016-06-15 | 2016-06-21 | ETOPOSIDE + IFOSFAMIDE + RITUXIMAB | 02 | N | 240012243 | DHAP - R |
| 240012532 | 240008728 | null | 75 | Curative (C) | 2015-04-16 | 2015-04-18 | ETOPOSIDE | N | N | 240012266 | DHAP - R |
| 240012533 | 240008729 | 1.75 | 84.2 | Disease modification (D) | 2016-08-29 | 2016-08-30 | AML17 TRIAL | 02 | N | 240012308 | CYTARABINE HIGH DOSE |
| 240012534 | 240008730 | 1.72 | null | Curative (C) | 2015-10-12 | 2015-10-12 | Fludarabine + Melphalan RIC Allo | null | null | 240012308 | BEVACIZUMAB + CISPLATIN + PACLITAXEL |
| 240012535 | 240015437 | 1.54 | 71.6 | Curative (C) | 2018-09-08 | 2018-09-10 | ECHELON-2 TRIAL | N | N | 240012317 | CYTARABINE HD + METHOTREXATE HD |
| 240012536 | 240012663 | 1.62 | 79.8 | Adjuvant (A) | 2013-05-13 | 2013-05-14 | CAV | N | N | 240012325 | CLADRIBINE |
| 240012537 | 240008733 | 1.63 | 57.8 | Adjuvant (A) | 2015-12-24 | 2015-12-25 | Capecitabine + Oxaliplatin 14day | N | null | 240012393 | CARBOPLATIN + TOPOTECAN |
| 240012538 | 240012664 | 1.78 | 58.7 | Curative (C) | 2017-11-02 | 2017-11-02 | Nilotinib | N | null | 240012393 | ESHAP R |
| 240012539 | 240008735 | null | 90.4 | Palliative (P) | 2013-12-25 | 2013-12-29 | CAPECITABINE + OXALIPLATIN | N | N | 240012407 | CYTARABINE HIGH DOSE |
| 240012540 | 240008736 | 1.73 | null | Curative (C) | 2016-12-31 | 2016-12-31 | ICE-R | N | N | 240012421 | RUXOLITINIB |
| 240012541 | 240008738 | 1.63 | 69.5 | null | 2014-06-10 | 2014-06-10 | Temozolomide 150mg/m2 | 02 | N | 240012438 | RCEOP |
| 240012542 | 240008739 | 1.58 | 92.6 | Palliative (P) | 2017-02-25 | 2017-02-25 | CVP | 2 | N | 240012479 | IVE |
| 240012543 | 240012667 | 1.69 | 53 | Palliative (P) | 2018-10-24 | 2018-10-25 | Gemcitabine + Oxaliplatin | 02 | Y | 240012479 | CARBOPLATIN + TOPOTECAN |
| 240012544 | 240008742 | 1.8 | null | null | 2016-07-24 | 2016-07-28 | Cytarabine HD + Methotrexate HD | null | null | 240012886 | CVP |
| 240012545 | 240014517 | 1.8 | 79.8 | Curative (C) | 2018-06-24 | 2018-06-24 | ICE-R | 2 | N | 240013177 | RCEOP |
| 240012546 | 240008744 | 1.75 | 54 | null | 2017-04-29 | 2017-04-29 | Cladribine IV weekly | N | N | 240013212 | IVAC |
| 240012547 | 240008744 | 1.64 | 55.9 | null | null | 2017-07-30 | ALEMTUZUMAB + BUSULFAN + FLUDARABINE | N | null | 240013212 | DOXORUBICIN |
| 240012548 | 240008745 | 1.57 | 61.8 | Curative (C) | 2019-06-26 | 2019-09-20 | DA-EPOCH-R | N | N | 240013365 | CYTARABINE + METHOTREXATE HD |
| 240012549 | 240008746 | 1.69 | 90.5 | Palliative (P) | 2014-06-06 | 2014-06-10 | IVAC | N | N | 240013419 | ETOPOSIDE |
| 240012550 | 240015440 | null | 55.4 | Curative (C) | 2018-05-03 | 2018-05-04 | VAC | N | null | 240013608 | DABRAFENIB + TRAMETINIB |
| 240012551 | 240008749 | 1.75 | 62.35 | Palliative (P) | 2014-05-30 | 2014-05-30 | Cytarabine HD + Methotrexate HD | N | N | 240013888 | AML17 TRIAL |
| 240012552 | 240008750 | 1.62 | 59.9 | Curative (C) | 2017-12-05 | 2017-12-17 | Cisplatin + Paclitaxel | N | null | 240013888 | SORAFENIB |
| 240012553 | 240008751 | null | 54 | Palliative (P) | 2017-08-16 | 2017-10-03 | Topotecan IV 7 day | N | N | 240014228 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE |
| 240012554 | 240008752 | null | null | null | 2018-07-04 | 2018-07-04 | Bevacizumab+Carbo+Gemcitabine | N | null | 240014228 | PONATINIB |
| 240012555 | 240014521 | 1.63 | 44.3 | Palliative (P) | 2017-05-07 | 2017-05-18 | Trabectedin | 2 | N | 240014568 | CYTARABINE INTRATHECAL |
| 240012556 | 240008756 | 1.78 | 75.2 | Disease modification (D) | 2016-10-23 | 2016-10-28 | PEMBROLIZUMAB | N | N | 240014619 | CRIZOTINIB |
| 240012557 | 240008759 | 1.62 | 49 | Curative (C) | 2016-11-02 | 2016-11-07 | CVP | N | N | 240014722 | CAPECITABINE + OXALIPLATIN |
| 240012558 | 240008760 | 1.71 | 48.4 | Palliative (P) | null | 2017-05-23 | BENDAMUSTINE + BORTEZOMIB | N | null | 240014722 | CLOFARABINE + CYTARABINE |
| 240012559 | 240008763 | 1.76 | 84.2 | Disease modification (D) | 2015-11-30 | 2015-12-07 | ESHAP R | N | null | 240014781 | MERCAPTOPURINE |
| 240012560 | 240014522 | 1.59 | 65 | null | 2016-02-04 | 2016-05-10 | Doxorubicin + Olaratumab | N | N | 240015079 | CLADRIBINE |